An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries
Saved in:
| Title: | An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries |
|---|---|
| Authors: | Steven G. Morgan, Chester B. Good, Christine Leopold, Anna Kaltenboeck, Peter B. Bach, Anita Wagner |
| Source: | Health Policy. 122:1012-1017 |
| Publisher Information: | Elsevier BV, 2018. |
| Publication Year: | 2018 |
| Subject Terms: | Prescription Drugs, Drug Costs/statistics & numerical data, Developed Countries, 1. No poverty, Drug Costs, Insurance Coverage, United States, 3. Good health, Health Expenditures/statistics & numerical data, 03 medical and health sciences, 0302 clinical medicine, Universal Health Insurance, Prescription Drugs/economics, Humans, Health Expenditures |
| Description: | We sought to estimate size and sources of differences in per capita expenditures on primary care medications in the US versus ten comparable countries combined: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom.Using market research data on year 2015 volumes and sales of medicines, we measure total per capita expenditures on six categories of primary care prescription drugs: hypertension treatments, pain medications, lipid lowing medicines, non-insulin diabetes treatments, gastrointestinal preparations, and antidepressants. We quantified the contributions of five drivers of the observed differences in per capita expenditures.We estimated that the US spent 203% more per capita on primary care pharmaceuticals than did the ten comparable countries. Despite the difference in spending levels, on average, Americans actually purchased 12% fewer days of related therapies than residents of the comparator countries. Most of the observed difference in expenditures was due to higher transaction prices of medicines and the use of a more expensive mix of medicines in the US.If utilization patterns and pharmaceutical prices in the US were similar to those in the 10 comparator countries combined, total spending on primary care pharmaceuticals would fall by 30% or more. Such evidence on the level and drivers of US pharmaceutical expenditures should inform policies in this sector. |
| Document Type: | Article |
| Language: | English |
| ISSN: | 0168-8510 |
| DOI: | 10.1016/j.healthpol.2018.07.005 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/30041827 https://research-portal.uu.nl/en/publications/2a4f9ca1-576e-49da-bf3c-8ae4664172e7 https://doi.org/10.1016/j.healthpol.2018.07.005 https://ideas.repec.org/a/eee/hepoli/v122y2018i9p1012-1017.html https://www.sciencedirect.com/science/article/pii/S016885101830246X https://www.ncbi.nlm.nih.gov/pubmed/30041827 https://www.cabdirect.org/cabdirect/abstract/20193013146 http://europepmc.org/article/MED/30041827 https://pubmed.ncbi.nlm.nih.gov/30041827/ |
| Rights: | Elsevier TDM |
| Accession Number: | edsair.doi.dedup.....ff9c873d5cef4219b4edda9f896b486b |
| Database: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | We sought to estimate size and sources of differences in per capita expenditures on primary care medications in the US versus ten comparable countries combined: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom.Using market research data on year 2015 volumes and sales of medicines, we measure total per capita expenditures on six categories of primary care prescription drugs: hypertension treatments, pain medications, lipid lowing medicines, non-insulin diabetes treatments, gastrointestinal preparations, and antidepressants. We quantified the contributions of five drivers of the observed differences in per capita expenditures.We estimated that the US spent 203% more per capita on primary care pharmaceuticals than did the ten comparable countries. Despite the difference in spending levels, on average, Americans actually purchased 12% fewer days of related therapies than residents of the comparator countries. Most of the observed difference in expenditures was due to higher transaction prices of medicines and the use of a more expensive mix of medicines in the US.If utilization patterns and pharmaceutical prices in the US were similar to those in the 10 comparator countries combined, total spending on primary care pharmaceuticals would fall by 30% or more. Such evidence on the level and drivers of US pharmaceutical expenditures should inform policies in this sector. |
|---|---|
| ISSN: | 01688510 |
| DOI: | 10.1016/j.healthpol.2018.07.005 |